Literature DB >> 10466895

Hypothesis: amyloid beta-peptides truncated at the N-terminus contribute to the pathogenesis of Alzheimer's disease.

A J Larner1.   

Abstract

Fragments of amyloid beta-peptide truncated at the N-terminus are present in AD brain early in the course of Alzheimer's disease. It is proposed that these species contribute to the pathogenesis of AD, possibly through destabilization of elements of the neuronal cytoskeleton by small fibrillar deposits.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10466895     DOI： 10.1016/s0197-4580(99)00014-7

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN： 0197-4580            Impact factor:   4.673


  9 in total

1.  C-terminal fragments of amyloid-beta peptide cause cholinergic axonal degeneration by a toxic effect rather than by physical injury in the nondemented human brain.

Authors:  Peter Kasa; Henrietta Papp; Janos Zombori; Peter Mayer; Frederic Checler
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

2.  In vitro studies of amyloid beta-protein fibril assembly and toxicity provide clues to the aetiology of Flemish variant (Ala692-->Gly) Alzheimer's disease.

Authors:  D M Walsh; D M Hartley; M M Condron; D J Selkoe; D B Teplow
Journal:  Biochem J       Date:  2001-05-01       Impact factor: 3.857

3.  Dense-core senile plaques in the Flemish variant of Alzheimer's disease are vasocentric.

Authors:  Samir Kumar-Singh; Patrick Cras; Rong Wang; John M Kros; Johan van Swieten; Ursula Lübke; Chantal Ceuterick; Sally Serneels; Krist'l Vennekens; Jean-Pierre Timmermans; Eric Van Marck; Jean-Jacques Martin; Cornelia M van Duijn; Christine Van Broeckhoven
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

Review 4.  Is the p3 Peptide (Aβ17-40, Aβ17-42) Relevant to the Pathology of Alzheimer's Disease?1.

Authors:  Ariel J Kuhn; Jevgenij Raskatov
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

5.  N-Terminal Extensions Retard Aβ42 Fibril Formation but Allow Cross-Seeding and Coaggregation with Aβ42.

Authors:  Olga Szczepankiewicz; Björn Linse; Georg Meisl; Eva Thulin; Birgitta Frohm; Carlo Sala Frigerio; Michael T Colvin; Angela C Jacavone; Robert G Griffin; Tuomas Knowles; Dominic M Walsh; Sara Linse
Journal:  J Am Chem Soc       Date:  2015-11-17       Impact factor: 15.419

6.  Immunodominant epitope and properties of pyroglutamate-modified Abeta-specific antibodies produced in rabbits.

Authors:  G Acero; K Manoutcharian; V Vasilevko; M E Munguia; T Govezensky; G Coronas; A Luz-Madrigal; D H Cribbs; G Gevorkian
Journal:  J Neuroimmunol       Date:  2009-07-09       Impact factor: 3.478

7.  Probing the effect of amino-terminal truncation for Abeta1-40 peptides.

Authors:  Takako Takeda; Dmitri K Klimov
Journal:  J Phys Chem B       Date:  2009-05-14       Impact factor: 2.991

Review 8.  The potential of pathological protein fragmentation in blood-based biomarker development for dementia - with emphasis on Alzheimer's disease.

Authors:  Dilek Inekci; Ditte Svendsen Jonesco; Sophie Kennard; Morten Asser Karsdal; Kim Henriksen
Journal:  Front Neurol       Date:  2015-05-11       Impact factor: 4.003

9.  Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy.

Authors:  Roxanna Perez-Garmendia; Goar Gevorkian
Journal:  Curr Neuropharmacol       Date:  2013-09       Impact factor: 7.363
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.